Bevacizumab and Platinum Choice in Pembrolizumab-Treated Advanced Cervical Cancer.

JAMA Netw Open · 2026 · PMC13370305 · PMID 42446878

Europe PMC DOI

hedged sentence

0.0500

closest p · 1.0× alpha

0.0500

boldest claim

The sentences

did not reach statistical significanceP = .05actually significant

The rate of pulmonary embolism was 29 of 455 (6.4%) in bevacizumab-treated patients and 45 of 455 (9.9%) in patients without bevacizumab, representing a difference that did not reach statistical significance (OR, 0.62 [95% CI, 0.38-1.01]) ( P = .05) (eFigure 4 in Supplement 1 ).

also in 58,632 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.